What's in Macrocure Ltd.'s pipeline?

Macrocure Ltd. has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Macrocure Ltd.'s portfolio?

Top competitors by shared drug class: Tasly Biopharmaceuticals Co., Ltd., The George Institute.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/macrocure-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Macrocure Ltd. — Portfolio Competitive Intelligence Brief

Macrocure Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
CureXcell	CureXcell	phase 3	Thrombolytic	Fibrin	Cardiovascular

Therapeutic area mix

Cardiovascular · 1
Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Tasly Biopharmaceuticals Co., Ltd. · 1 shared drug class
The George Institute · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Macrocure Ltd.:

Cite this brief

Drug Landscape (2026). Macrocure Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/macrocure-ltd. Accessed 2026-05-13.